326030 — SK Biopharmaceuticals Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩7tn
- KR₩7tn
- KR₩355bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 82,374 | 387,991 | 334,339 | 305,454 | 241,118 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,546 | 12,638 | 61,675 | 67,021 | 115,847 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 98,681 | 434,603 | 471,219 | 487,925 | 488,722 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 25,897 | 24,233 | 22,938 | 20,350 | 47,753 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 139,073 | 500,241 | 643,652 | 664,241 | 723,171 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 145,641 | 70,595 | 148,306 | 163,073 | 241,619 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 152,098 | 121,175 | 199,465 | 347,681 | 439,484 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | -13,025 | 379,067 | 444,187 | 316,560 | 283,686 |
Total Liabilities & Shareholders' Equity | 139,073 | 500,241 | 643,652 | 664,241 | 723,171 |
Total Common Shares Outstanding |